Development and commercialization of innovative medicines in various therapeutic areas, including gastrointestinal diseases, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines.
B
CSR Analysis score
The organization is among the top 20% of most committed organizations, excluding the top 5%, among comparable organizations.
+160,000
Total organizations analyzedAnalysis by axis
Access the detailed report with all sector benchmarks, in-depth competitive analysis and actionable recommendations.
Methodology: Score calculated according to 6 CSR themes (Carbon, Biodiversity, Circular Economy, Sustainable Investments, Governance, Social Impact)
Sources: Public data, CSR reports, documented initiatives, official databases
Last update: December 2025
This analysis is not yet available in English. Please see the French version.
Leading organizations
Orphan Europe
B
Development and commercialization of drugs for rare diseases.
MSD France
B
Development of innovative medicines and vaccines to address major public health challenges and improve population health.
Medincell
A
Development of innovative pharmaceutical and biotechnology products, focusing on advanced drug delivery systems.
Initiatives identified among leaders
Participer au développement des Objectifs de Développement Durable
“Medincell participe au développement des Objectifs...” - MedincellRéduction des émissions de gaz à effet de serre
“MSD France prend des mesures pour réduire les émis...” - MSD FranceSoutenir les communautés locales
“Orphan Europe soutient les communautés locales, en...” - Orphan Europe63% of similar organizations communicate on CSR issues
+4415 initiatives collected from 100 similar organizations
Is your score incomplete? Update your CSR information and improve your positioning.
Claim this page
Updated data
Personalized recommendations
Access complete data, competitive analyses and actionable recommendations for your clients.
Comprehensive sector benchmarks
Competitive data
Ready-to-use reports